Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Q2 Losses Up on Lower Revenues, Higher Expenses

Premium

Tekmira Pharmaceuticals this week reported a jump in its second-quarter net loss as revenues shrank and expenses increased.

For the three-month period ended June 30, Tekmira's net loss rose to $4.2 million from $2.3 million in the same period a year earlier.

Contributing to the higher loss was a decline in revenues to $2.3 million from $3.8 million, which the company attributed to fluctuations in demand for its manufacturing services and the timing of milestone payments from collaborators.

Research, development, and collaboration spending increased in the quarter to $4.8 million from $4.4 million, reflecting the costs associated with preparations for clinical testing of two of Tekmira's drug candidates, the hypercholesterolemia treatment TKM-ApoB (formerly ApoB SNALP) and TKM-PLK1 (formerly PLK1 SNALP).

General and administrative costs were flat at $1.1 million.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.